

Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan

Share capital increase successfully completed and fully subscribed for an amount equal to Euro 49,824,834.53

Milan, 9 April 2015 – MolMed S.p.A. (“**MolMed**” or the “**Company**”) announces that the rights offering (the “**Offering**”) of No. 187,311,408 newly issued MolMed ordinary shares (the “**Shares**”) has been successfully completed.

During the offering period, which started on 9 March 2015 and ended on 30 March included, (the “**Offering Period**”), No. 184,693,240 rights were exercised for the subscription of No. 147,754,592 Shares, equal to 99.24% of the total offered Shares, for a total amount equal to Euro 39,302,721.48 net of the amount of Euro 10,144,774.00 anticipated as an advance payment on future share capital increase by shareholders Fininvest S.p.A., Airain Ltd., H-Equity S.r.l. and H-Invest S.p.A.. In particular, Fininvest, Airain, H-Equity and H-Invest have subscribed the share capital increase under the terms and conditions already disclosed to the market.

Pursuant to Article 2441, third paragraph, of the Italian Civil Code, MolMed offered on the Milan Stock Exchange (the “**Offer to the Market**”) No. 1,773,220 option rights that were not exercised during the Offering Period (the “**Unexercised Rights**”).

All the Unexercised Rights have been sold during the second trading session of the Offer to the Market, held on 2 April 2015, for a total amount equal to Euro 178,208.61. Following the Offer to the Market, all the No. 1,418,576 Shares from the exercise of the Unexercised Rights have been subscribed.

Therefore, the Offering was completed with the full subscription of the No. 187,311,408 Shares, for a total amount of Euro 49,824,834.53.

At the end of the Offering, considering the participation of the shareholders Fininvest, Airain, H-Equity and H-Invest, MolMed’s new share capital amounts to Euro 19,841,682.30, represented by No. 421,450,672 ordinary shares with no par value. The relevant certification required pursuant to Article 2444 of the Italian Civil Code will be filed with the Companies’ Register of Milan within the term provided by law.

This press release is written in compliance with public disclosure obligations established by CONSOB (Italian securities & exchange commission) resolution no. 11971 of 14 May 1999, as subsequently amended.

NOT FOR DISTRIBUTION IN THE UNITED STATES, AUSTRALIA, CANADA OR JAPAN

This communication does not constitute an offer or an invitation to subscribe for or purchase any Securities. The securities referred to herein have not been registered and will not be registered in the United States under the U.S. Securities Act of 1933, as amended (the “**Securities Act**”) , or in Australia, Canada or Japan or any other jurisdiction where such an offer or solicitation would require the approval of local authorities or otherwise be unlawful. The securities may not be offered or sold in the United States or to U.S. persons unless such securities are registered under the Securities Act, or an exemption from the registration

FROM GENES TO THERAPY

MOLMED S.p.A.

Via Olgettina, 58 - 20132 Milan, Italy | Phone +39 02 21277.1 - Fax +39 02 21277.325
info@molmed.com - www.molmed.com

Share capital € 11,019,314.98 fully paid - Office of Milan Company Registry number 1506630 - Tax identification number 11887610159



Not for distribution, directly or indirectly, in the United States of America, Australia, Canada or Japan

requirements of the Securities Act is available. Copies of this announcement are not being made and may not be distributed or sent into the United States, Canada, Australia or Japan.

About MolMed

MolMed S.p.A. is a biotechnology company focused on research, development and clinical validation of novel anticancer therapies. MolMed's pipeline includes two antitumour therapeutics in clinical development: TK, a cell-based therapy enabling bone marrow transplants from partially compatible donors, in absence of post-transplant immune-suppression, in Phase III in high-risk acute leukaemia; NGR-hTNF, a novel vascular targeting agent, in Phase III in malignant pleural mesothelioma and in Phase II in six more indications: colorectal, lung (small-cell and non-small-cell), liver and ovarian cancer, and soft tissue sarcomas. MolMed also offers top-level expertise in cell and gene therapy to third parties to develop, conduct and validate projects from preclinical to Phase III trials, including scale-up and cGMP production of clinical-grade viral vectors, and manufacturing of patient-specific genetically engineered cells. MolMed is headquartered at the San Raffaele Biomedical Science Park in Milan, Italy. The Company's shares are listed on the main market (MTA) of the Milan Stock Exchange. (Ticker Reuters: MLMD.MI)

For further information:

Marina Del Bue

**General Manager Corporate Governance & Administration
Investor Relations Director *ad int.***

MolMed S.p.A.

phone: +39 02 21277.371

fax: +39 02 21277.325

e-mail: investor.relations@molmed.com

Press agent

Federico Ferrari

SEC Relazioni Pubbliche e Istituzionali srl

phone: +39 02 6249991 – mobile +39 347 6456873

e-mail: ferrari@secrp.it

DISCLAIMER

This press release may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, including scientific, business, economic and financial factors, which could cause actual results to differ materially from those anticipated in the forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of MolMed S.p.A.